Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders

K Ohno, B Ohkawara, M Ito - Expert Opinion on Therapeutic Targets, 2017 - Taylor & Francis
Introduction: Signal transduction at the neuromuscular junction (NMJ) is compromised in a
diverse array of diseases including myasthenia gravis, Lambert-Eaton myasthenic …
被引用次数：55 相关文章

Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders

K Ohno, B Ohkawara, M Ito - Expert Opinion On Therapeutic Targets, 2017 - hero.epa.gov
INTRODUCTION: Signal transduction at the neuromuscular junction (NMJ) is compromised
in a diverse array of diseases including myasthenia gravis, Lambert-Eaton myasthenic …

[引用][C] Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders

K Ohno, B Ohkawara, M Ito - Expert Opinion on Therapeutic Targets, 2017 - cir.nii.ac.jp
Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other
neuromuscular disorders | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …

Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders

K Ohno, B Ohkawara, M Ito - Expert opinion on therapeutic …, 2017 - pubmed.ncbi.nlm.nih.gov
Signal transduction at the neuromuscular junction (NMJ) is compromised in a diverse array
of diseases including myasthenia gravis, Lambert-Eaton myasthenic syndrome, Isaacs' …

Agrin-LRP4-MuSK signaling as a therapeutic target for myasthenia gravis and other neuromuscular disorders.

K Ohno, B Ohkawara, M Ito - Expert Opinion on Therapeutic Targets, 2017 - europepmc.org
Signal transduction at the neuromuscular junction (NMJ) is compromised in a diverse array
of diseases including myasthenia gravis, Lambert-Eaton myasthenic syndrome, Isaacs' …